Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

This article is part of the supplement: Breast Cancer Research 2010

Poster presentation

Polymorphisms, endogenous hormone levels and familial breast cancer risk in premenopausal women

K Walker1*, O Fletcher2, N Johnson2, C Palles2, E Folkerd3, SG Hillier4, S Moss5, L Gibson1, M Dowsett6, J Peto17 and I dos santos Silva1

  • * Corresponding author: K Walker

Author Affiliations

1 London School of Hygiene and Tropical Medicine, London, UK

2 Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

3 The Institute of Cancer Research, London, UK

4 Centre for Reproductive Biology, The University of Edinburgh, UK

5 Cancer Screening Evaluation Unit, The Institute of Cancer Research, Sutton, UK

6 The Academic Department of Biochemistry, The Royal Marsden Hospital, London, UK

7 Cancer Research UK Epidemiology and Genetics Group, The Institute of Cancer Research, Sutton, UK

For all author emails, please log on.

Breast Cancer Research 2010, 12(Suppl 1):P25  doi:10.1186/bcr2522

The electronic version of this article is the complete one and can be found online at:

Published:18 May 2010

© 2010 BioMed Central Ltd.


Epidemiological studies provide strong evidence of a role for endogenous sex hormone levels in the aetiology of breast cancer [1] and suggest that levels may be partly genetically determined. Quantification of hormone levels in premenopausal women, however, is difficult because of their cyclical nature. In particular, oestrogen has a marked peak in the follicular phase and a further wider peak in the luteal phase.


We developed a protocol to capture peak follicular phase urinary oestrone glucuronide (E1G), and luteal phase E1G in healthy premenopausal women. Repeated measurements of creatinine-adjusted E1G levels, in 789 women, were used to describe features of the E1G curve such as mean and peak follicular E1G, and luteal E1G. A total of 691 tagging SNPs capturing common variation in genes within the oestrogen synthesis and metabolism pathways were successfully genotyped. Geometric mean urinary E1G levels and endogenous plasma hormone levels were estimated and tested for an association with the genotype of each SNP.


We identified a rare SNP (minor allele frequency 7%), in which the minor allele was associated with a 20% reduction in circulating levels of E1G in healthy premenopausal women (P < 10-8). We are currently genotyping this SNP in 12,000 breast cancer cases and 12,000 controls to test whether the reduction in circulating oestrogen levels is also associated with a reduction in breast cancer risk.


Circulating hormone levels in premenopausal women may provide a useful intermediate phenotype in the search for low-penetrance breast cancer risk alleles.


  1. The Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

    J Natl Cancer Inst 2002, 94:606-616. PubMed Abstract | Publisher Full Text OpenURL